RAJAF — Cordyceps Sunshine Biotech Holdings Co Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMid Cap
- $951.19m
- $951.60m
- $0.88m
Annual cashflow statement for Cordyceps Sunshine Biotech Holdings Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 20-F | 20-F |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.013 | -0.491 | -0.72 | 0.242 |
| Depreciation | ||||
| Deferred Taxes | ||||
| Non-Cash Items | 0.002 | 0.396 | 0.145 | 0.215 |
| Discontinued Operations | ||||
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -0.146 | -0.419 | 0.085 | -0.146 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -0.131 | -0.365 | -0.321 | 0.325 |
| Capital Expenditures | -1.11 | -0.111 | -0 | -0.207 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -0.389 | — | — | 0.086 |
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -1.5 | -0.111 | -0 | -0.122 |
| Financing Cash Flow Items | 1.22 | 0.342 | 0.246 | -0.26 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 1.63 | 0.575 | 0.246 | -0.26 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0 | 0.099 | -0.084 | -0.001 |